Clinical Research Of Chaiguaxie Decoction In The Treatment Of Herpes Zoster With Liver Meridian Heat Retention

Objective: To study the clinical effect of Chaiguaxie Decoction in the treatment of Herpes zosterthe(type of liver meridian heat retention),and its effect on the duration of the disease,the degree of pain relief,the incidence of adverse reactions,the incidence of postoperative neuralgia,the quality of life and complement C3 and C4 levels.Methods: This study included 75 patients in the treatment group(n=37cases)and the control group(n=38 cases)according to the random number table method.The treatment group was treated with oral Chaiguaxie Decoction and the control group with oral valaciclovir hydrochloride capsule.Both groups were treated for 7 days,and peripheral blood complement C3 and C4 levels were detected at the beginning and end of treatment,as well as related routine examinations.Pain score before and after treatment;Quality of life scores were performed at the beginning and 3 months after the study ended.After the treatment,the duration,cure rate and total effective rate of the two groups were compared.Whether there was postherpetic neuralgia or not in the patients who were followed up by telephone 3 months after the end of the study and their incidence was calculated;The adverse reactions of the patients and their safety were recorded in time during the experiment,so as to comprehensively evaluate the clinical efficacy of Chaiguaxie Decoction in the treatment of Herpes zoster with liver meridian heat retention.Results:(1)In this study,a total of 5 cases were exfoliated and lost to follow-up.Finally,70 patients were included,35 in the treatment group and 35 in the control group.The baseline of the treatment group was consistent with that of the control group.(2)comparison of pain score: after treatment,the pain score of both groups decreased compared with that before treatment,with statistically significant difference(P<0.05).However,the pain score of the treatment group was lower,with statistically significant difference(P<0.05),indicating that the treatment group was more effective in alleviating the pain degree of patients with shingles.(3)treatment course comparison: after treatment,the time of stopping vesicles,scabbing time,dislocation time and pain relief time of the treatment group were significantly lower than that of the control group,with statistically significant differences(P<0.05),indicating that the treatment group could shorten the course of disease compared with the control group.(4)clinical efficacy evaluation: after treatment,the total clinical effective rate of the treatment group was 88.57%,higher than that of the control group(77.14%),with statistically significant difference(P<0.05).The results showed that the effect of the treatment group was better than that of the control group.(5)comparison of quality of life scores: after treatment,both groups had lower DLQI scale scores than before treatment,with statistically significant differences(P<0.05).However,compared with the control group,the improvement in the treatment group was significant,with statistically significant differences(P<0.05).(6)incidence and safety evaluation of adverse reactions: no significant abnormalities were found in the routine examination of hematuria and liver and kidney function before and after treatment in the two groups.In the treatment group,adverse reactions occurred in 2 cases,with an incidence of 5.71%.Adverse reactions occurred in 3 patients in the control group,and the incidence of adverse reactions was 8.57%.There was no significant difference between the two groups(P>0.05),indicating no significant difference in the incidence of adverse reactions between the two groups.(7)comparative analysis of complement C3 and C4 levels:after treatment,complement C3 and C4 levels in the two groups were significantly higher than before treatment,but the increase was more significant in the treatment group,with statistically significant difference(P<0.05).(8)comparison of incidence of postherpetic neuralgia: 3 months after the end of treatment,telephone follow-up showed that 4 cases of postherpetic neuralgia occurred in the treatment group,and the incidence of postherpetic neuralgia was 11.43%;15 cases of postherpetic neuralgia occurred in the control group,and the incidence of postherpetic neuralgia was 42.86%.The incidence of posthumous neuralgia in the treatment group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:(1)Compared with valaciclovir hydrochloride capsule,Chaiguaxie Decoction can relieve the pain,shorten the course of treatment,improve the clinical effect,improve the quality of life,improve the level of serum complement C3、C4 and reduce the incidence of neuralgia.(2)in terms of drug safety and reducing the incidence of adverse reactions,Chaiguaxie Decoction and valaciclovir hydrochloride capsules have the same effect.(3)the mechanism of Chaiguaxie Decoction may be related to the regulation of immune system such as C3 and C4 in peripheral blood complement of Herpes zoster patients.